IFW POXSED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/552,660 Applicant : Yan HONG

Filed : October 11, 2005

TC/A.U. : 1646

Examiner

Docket No. : 2577-158
Customer No. : 06449
Confirmation No. : 1905

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

#### RESPONSE TO NOTICE TO COMPLY

#### Dear Sir:

In response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures (copy herewith), enclosed please find a replacement copy of the "Sequence Listing" in computer readable form.

It is hereby certified that the sequence information contained in the computer readable copy is identical to the paper copy of the "Sequence Listing" in the application as filed. A paper copy of the "Sequence Listing" is also included with this paper.

The Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures further asserts that additional claims fees of \$50 are required for the application. As a first matter, the transmittal letter filed with the application referenced above authorized the Commissioner to charge any additional fees that may be required to respondent's deposit account. Thus, no further fees should have been required. However, a review of the

application as filed indicates that the application contains 21 claims, as was correctly indicated on the PTO Form 1390 transmittal letter. This paper provides a copy of the claims from the application as filed on October 11, 2005 and a copy of the PTO Form 1390.

Respectfully submitted,

y Dull

Barbara W. Walker

Attorney for Applicants Registration No. 35,400

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

Suite 800, 1425 K Street, N.W.

Washington, D.C. 20005 Telephone: (202)783-6040



#### United States Patent and Trademark Office

United States Patent and Trademark Office
Address COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

U.S. APPLICATION NUMBER NO.		FIRST NAMED APPLICANT	,	ATTY.	DOCKET NO.	
10/552,660	`	Yan Hong	2577-158		577-158	
	<b>C</b> arrier and	Hedenfortablines Ne <u>ll Hee</u> enis <mark>a</mark> nd	INTERNATIONAL APPLICATION NO.		JICATION NO.	
	FILE NO.L	FILE NO. 2577-158-		PCT/SG04/00093		
6449 ROTHWELL, FIGG, ERNST & MANBEO	FAG MICO.	. E. CEW/CEW	I.A. FILI	ING DATE	PRIORITY DATE	
1425 K STREET, N.W.	JN, P.U.		04/14	4/2004	04/14/2003	
SUITE 800		JUN 12 2006 M	<i>/</i> A			
WASHINGTON, DC 20005		1"		CONFIRMA	<b>ATION NO. 1905</b>	
	DKT GNORY MOS A 371 FORMALITIES LETTER					
•	SEND TO: GAP LOW IIII IIII IIII IIII IIII IIII IIII					
·	OK TO FILE	:	*OC0000000	19157262*		

Date Mailed: 06/08/2006

### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

 Additional claim fees of \$50 as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.

#### SUMMARY OF FEES DUE:

Total additional fees required for this application is \$50 for a Large Entity:

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- Total additional claim fee(s) for this application is \$ 50
  - \$50 for 2 total claims over 20.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

SHELBY J VIGIL

Telephone: (703) 308-9140 EXT 224

#### PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/552,660	PCT/SG04/00093	2577-158

FORM PCT/DO/EO/922 (371 Formalities Notice)

				_		
FORM PTO-1390		0 ,	U.S. Department of Commerce Patent and Trademark Office	Attomey's Docket No.		
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) OCCUPATION OF THE UNITED STATES OF TRANSMITTAL LETTER TO THE UNITED STATES OF TRANSMITTAL LETTER TO THE UNITED STATES OF TRANSMITTAL LETTER TO THE UNITED STATES			2577-158			
				U.S. Application No. (if known)		
N 2 .	N 2 1 12 BOSIGE AND AND ENGLISHED STORES OF THE STORES OF		New Application			
INTER	INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE 14 April 2004			PRIORITY DATE CLAIMED 14 April 2003		
	TITLE OF INVENTION					
	DETECTION OF TRANSGENES OF GENETICALLY MODIFIED ORGANISMS USING PYRO LUMINESCENCE APPLICANT(S) FOR DO/EO/US					
Yan H						
Applica informa			States Designated/Elected Office (DO/EO/	US) the following items and other		
1. [)	<b>x</b> ]	This is a <b>FIRST</b> submission of	of items concerning a filing under 35 U.S.C.	371		
2. [	]	This is a SECOND or SUBS	EQUENT submission of items concerning a	filing under 35 U.S.C. 371.		
3. [X] This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.						
4. [)	. [X] The US has been elected (Article 31).					
5. [)	<ul> <li>a. [ ] is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. [X] has been communicated by the International Bureau.</li> </ul>					
			the application was filed in the United State	, ,		
6. [	<ul> <li>6. [ ] An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</li> <li>a. [ ] is attached hereto.</li> <li>b. [ ] has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ul>					
7. [>	<ul> <li>7. [X] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</li> <li>a. [ ] are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. [X] have been communicated by the International Bureau.</li> <li>c. [ ] have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. [ ] have not been made and will not be made.</li> </ul>					
8. [	8. [ ] An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).					
9. [)	9. [X] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).					
10. [	<ol> <li>An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>					
ITEMS 11. TO 20. below concern other document(s) or information included:						
13. [X 14. [X 15. [X	( ] ( ]		nder 37 CFR 1.76.	pliance with		
	A power of attorney artificial change of address fetter.      A computer-readable form of the sequence listing in accordance with PCT Rule 13 <i>ter</i> .2 and 35 U.S.C. 1.821-1.825					
18. [ 19. [	]	A second copy of the published international application under 35 U.S.C. 154(d)(4).  A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).				

U.S. APPLICATION NO. (If known) New Application  INTERNATIONAL APPLICATION NO. PCT/SG2004/000093			ATTORNEY DOCKET NO. 2577-158		
-	items or informa	ition:		•	
	•	X   ISA/210(ISR) [] IB/301 [X] IB/304 [] IB/308 []	IB 401 [X] IB/4	109(IPER)	
[X] IB/	416 [X] Publish	ed Application WO/2004/090167 [ X ] ISA/237			
21. The following f	fees are submitt	ted:	:	CALCULATIONS	PTO USE ONLY
				\$ 300.00	
22. X Examir	nation Fee			\$ 200.00	
		or the IPER prepared by IPEA/US indicates	••		
		Article 33(1)-(4)			
23. Search	ı Fee			\$ 400.00	
		IPER prepared by IPEA/US indicates all claims	••		
Search fee (37 CFR 1.4	445(a)(2)) has bee	i(1)-(4) n paid on the international application			
International Search Re	eport prepared by a	Search Authorityan ISA other than the US and provided to the Office			
		US by the IB			
		TOTAL OF 2	21, 22 AND 23 =	\$ 900.00	
Additional fee for specification and drawings filed in paper over 100  (excluding sequence listing or computer program listing filed in an electronic medium).  The fee is \$250.00 for each additional 50 sheets of paper or fraction thereof.			\$		
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Rate		
- 100 =	/ 50 =		x 250	\$	,
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(h)).				\$	
Claims	Number Filed	Number Extra	Rate		
Total Claims	21 -20 =	1	X \$50.00	\$ 50.00	
Independent Claims	2 -3=		X \$200.00	\$	
Multiple dependent cla	im(s) (if applicable	2)	+ \$360.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$	
Applicant claims small entity status. The fees indicated above are reduced by 1/2.			\$		
· SUBTOTAL =			\$		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			\$		
. TOTAL NATIONAL FEE =			\$		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$		
accompanied by an appropriate cover sneer (37 GPR 3.28, 3.31). \$40.00 per property  TOTAL FEES ENCLOSED =				\$ 950.00	
				Amount to be refunded	\$
				Amount to be charged	\$

		INTERNATIONAL APPLICATION NO. PCT/SG2004/000093	ATTORNEY DOCKET NO. 2577-158		
а. 🗌	a. A check in the amount of \$ to cover the above fees is enclosed.				
b. X Please charge my Deposit Account No. 02-2135 in the amount of \$950.00 to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. X	c. X  The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-2135. A duplicate copy of this sheet is enclosed.				
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:  Signature  Signature					
Barbara Webb Walker Name Rothwell, Figg, Ernst & Manbeck 1425 K St., N.W. 35,400			***		

2577-158.Form1390.wpd



PCT/SG2004/000093 Received 17 February 2005

# BEST AVAILABLE COPY

#### **CLAIMS**

1. A method of identifying the presence of a transgene of a genetically modified organism in a sample wherein the nucleic acid of the transgene is replicated and detected as the release of pyrophosphate (PPi), the method comprising:

adding an oligonucleotide primer to the sample which hybridizes to the transgene; subjecting the sample nucleic acid and primer to a polymerase reaction in the presence of a mixture of deoxynucleotides required for replication of the transgene whereby the deoxynucleotides are incorporated and release PPi proportional to the length of the DNA extension product; and

detecting any release of PPi enzymatically; wherein release of PPi indicates the presence of the transgene.

- 2. The method of claim 1, wherein the transgene is replicated in a reaction selected from the group consisting of a polymerase extension reaction, a polymerase chain reaction (PCR), a ligase chain reaction (LCR), a rolling circle replication reaction (RCR) and a nucleic acid sequence based amplification reaction (NASBA).
- 3. The method of claim 2 wherein the transgene is replicated in a polymerase chain reaction.
- 4. The method of claim 1, wherein the release of PPi is detected by means of a Luciferase-Luciferin-based reaction.
- 5. The method of claim 1, wherein PPi release is detected using ATP sulfurylase and luciferase.
- The method of claim 1, wherein the PPi detection enzymes are

PCT/SG2004/000093 Received 17 February 2005

### DEOL AVAILABLE COPY

included in the polymerase reaction step and the polymerase reaction and PPi release detection steps are performed substantially simultaneously.

- 7. The method of claim 1, further comprising adding a dATP analogue which is capable of acting as a substrate for a polymerase, but incapable of acting as a substrate for a PPi detection enzyme.
- 8. The method of claim 7, wherein the dATP analogue is deoxyadenosine. alpha. thiotriphosphate.
- 9. The method of claim 1, wherein the sample DNA or oligonucleotide primer is immobilized or provided with means for attachment to a solid support.
- 10. The method of claim 1, for use with a multiplicity of sample DNA sequences, wherein said DNA sequences are arranged in assay format on a solid surface.
- 11. The method of claim 1, wherein said nucleic acid sample is from a plant.
- 12. The method of claim 11 wherein the plant is a food source.
- 13. A kit for detecting the presence of a transgene of a genetically modified organism in a sample as defined in claim 1, comprising:
  - a polymerase;
  - an enzyme detection means for identifying PPi release;

deoxynucleotides, or optionally deoxynucleotide analogues, optionally including, in place of dATP, a dATP analogue which is capable of acting as a substrate for a polymerase but incapable of acting as a substrate for a PPi-detection enzyme; and

optionally a transgene specific primer which hybridizes to the transgenic DNA and is recognized as a primer by a polymerase, wherein the polymerase replicates the transgenic DNA.

PCT/SG2004/000093 Received 17 February 2005

## BEST AVAILABLE COPY

- 14. The kit of claim 13, wherein the detection enzyme means comprises luciferin and luciferase.
- 15. The kit of claim 14, wherein the detection enzyme means comprises ATP sulfurylase and luciferase.
- 16. The kit of claim 13, wherein the transgene specific primer hybridizes to a transgene that provides herbicide resistance.
- 17. The kit of claim 16, wherein the transgene specific primer hybridizes to a transgene that provides resistance to the herbicides selected from glyphosate and glufosinate.
- 18. The kit of claim 13, wherein the transgene specific primer hybridizes to a transgene that provides insect resistance.
- 19. The kit of claim 13, wherein the transgene specific primer is selected from SEQ ID NOS. 1 to 29.
- 20. The method of claim 1, wherein the oligonuc eotide primer is selected from SEQ ID NOS. 1-29.
- 21. A method of detecting a transgene of a genetically modified organism in a sample that may contain nucleic acid from the genetically modified organism wherein the nucleic acid of the transgene is replicated and detected as release of pyrophosphate, the method comprising:

adding an oligonucleotide primer selected from SEQ ID NOS. 1 to 29 to the sample; subjecting the sample to a polymerase reaction; and detecting the release of PPi;

wherein the release of PPi indicates the presence of a transgene in the sample.